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Background: We describe the study design, procedures, and development of the risk counseling protocol used in
a randomized controlled trial to evaluate the impact of genetic testing for diabetes mellitus (DM) on psychological,
health behavior, and clinical outcomes.
Methods/Design: Eligible patients are aged 21 to 65 years with body mass index (BMI) ≥27 kg/m2 and no prior
diagnosis of DM. At baseline, conventional DM risk factors are assessed, and blood is drawn for possible genetic
testing. Participants are randomized to receive conventional risk counseling for DM with eye disease counseling or
with genetic test results. The counseling protocol was pilot tested to identify an acceptable graphical format for
conveying risk estimates and match the length of the eye disease to genetic counseling. Risk estimates are
presented with a vertical bar graph denoting risk level with colors and descriptors. After receiving either genetic
counseling regarding risk for DM or control counseling on eye disease, brief lifestyle counseling for prevention of
DM is provided to all participants.
Discussion: A standardized risk counseling protocol is being used in a randomized trial of 600 participants. Results
of this trial will inform policy about whether risk counseling should include genetic counseling.
Trial registration: ClinicalTrials.gov Identifier NCT01060540
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Genetic testing has become an increasingly viable option
for conveying the risk of developing complex chronic dis-
eases [1]. Genetic testing for this purpose currently is not
a routine part of primary care. Barriers may include a
lack of resources for testing, a lack of genetic counselors
to deliver the results, and uncertainty about whether
knowing genetic risk prompts risk reduction behaviors
[2]. Evidence of the clinical utility of providing genetic
testing results is needed to inform policy regarding the
use of genetic testing for complex chronic diseases in
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reproduction in any medium, provided the orDiabetes mellitus (DM) is an ideal prototype disease
for examining this issue for several reasons. First, DM is
a highly prevalent and costly chronic disease that results
in debilitating microvascular and macrovascular compli-
cations and impaired quality of life [3,4]. Second, genetic
abnormalities in complex chronic diseases such as DM
involve multiple genes such that testing determines dis-
ease risk [5]. This is in contrast to Mendelian disorders,
which result from a mutation in a single causative gene
and for which single-gene tests determine, definitively,
the presence or absence of disease, regardless of lifestyle
choices. Third, much is known about the environmental
and genetic contributors to the development of DM, and
the evidence suggests that behavior change is the best
way to prevent its development, even when gene poly-
morphisms are present [6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(RCT) to examine the comparative effectiveness of risk
counseling using conventional risk factors for DM versus
counseling that additionally includes genetic testing
results. In this article, we report on the study design,
procedures, and development of the counseling
protocol.
Methods/Design
Study design and overview
The ongoing study is a two-arm RCT to determine the ef-
fect of genetic testing for DM on clinical outcomes and
health behaviors. At baseline, participants provide written
informed consent, information for conventional risk as-
sessment, blood samples for fasting plasma glucose (FPG)
and possible genetic testing, and baseline clinical and
health behavior outcomes (Figure 1). Eligible participantsFigure 1 Study overview.are then randomized to receive conventional risk plus gen-
etic test result counseling (CR+G) or conventional risk
plus control eye disease counseling (CR+E), stratified by
family history (unknown/low vs. moderate/high) and body
mass index (BMI; < 35 vs. ≥ 35 kg/m2). Two to 4 weeks
following baseline, all participants return for a risk coun-
seling visit with a genetic counselor that does (CR+G) or
does not (CR+E) include delivery of genetic test results
and associated counseling. Psychological outcomes are
assessed immediately following counseling and at 3 and 6
months. Behavioral and clinical outcomes are assessed at 3
and 6 months, with 3 months as the primary endpoint.
Study population and recruitment
Participants are recruited from the Durham Veterans
Affairs Medical Center (VAMC) and satellite clinics.
Ethical approval was obtained from the Institutional
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tees at the Durham VAMC. Eligibility is confirmed by an
electronic data pull followed by a screening telephone
call and a baseline visit (see Table 1 for eligibility cri-
teria). A recruitment letter is mailed to patients meeting
inclusion criteria who have a clinical appointment in the
next 3 weeks. If patients do not opt out of the study by
calling a toll-free number, a research assistant (RA) con-
tacts them by phone within 2 weeks to describe the
study, assess interest, and administer a cognitive screen
[7]. Patients may also self-refer in response to flyers
posted in the medical center. Interested and eligible
patients are then scheduled for the baseline study visit.
Patients receive reminder letters with fasting instruc-
tions 1 week before their scheduled appointments and
reminder phone calls the day before their appointments.
Baseline visit
At the baseline visit, an RA describes the study, reviews
the risks and benefits of genetic testing, and reviews the
randomization process. After any questions are
addressed, participants provide written informed con-
sent. Participants are asked not to obtain genetic testing
from outside resources while enrolled in our study. Age,
sex, race, family history, weight, and height are collected
for use in calculating cumulative lifetime risk for DM.
History of DM is obtained for first- and second-degree
relatives. Upon confirmation that patients have fasted
for 12 h, blood is drawn for FPG, fasting insulin, and
possible genetic testing. Participants complete a measure
of numeracy [8], then the RA administers all other mea-
sures orally. Participants receive $25 for this 1-h visit.
Final study eligibility is determined based on the base-
line FPG results, usually available within 24 h.Table 1 Eligibility criteria and method of ascertainment
Criterion
Inclusion criteria Age 21–65 years
Body mass index≥ 27 kg/m2
Exclusion criteria Diagnosis of diabetes mellitus
Fasting plasma glucose≤ 125 mg/dl on more than one
Hemoglobin A1c >7%
Taking diabetes medication
Intentional weight loss of at least 5 lbs in previous 3 m
Enrolled in a research study or any program focused on
Unable to provide informed consent or answer survey
Residing in nursing home or receiving home health car
At least 1 error on a validated 6-item screen for cogniti
Fasting plasma glucose≤ 125 mg/dl at baselineRandomization
Participants are randomized to the CR+G versus the
CR+E arms in blocks within four strata defined by weight
status (BMI <35 kg/m2 vs. ≥ 35 kg/m2) * family history of
DM (unknown/low vs. moderate/high). We wanted to en-
sure balance in each arm on BMI status as weight trajec-
tories, and adherence to recommendations may differ
depending on severity of obesity. We also wanted to en-
sure balance on family history of DM in each arm as indi-
viduals with a strong family history may be more likely to
engage in preventive lifestyle changes [9]. The project co-
ordinator enters the values of the stratification variables
and FPG into the study database, and the randomly
assigned study arm is returned for eligible patients. Then,
due to budget constraints, only blood samples for CR+G
participants are sent for genetic testing.
Only the project coordinator and Master’s-level statisti-
cian have access to the randomization section of the study
database. RAs are blind to arm assignment, and arm as-
signment is not revealed to participants or the genetic
counselor until during the counseling session, after the
conventional risk counseling has been delivered. Because
randomization occurs prior to the genetic counseling ses-
sion (to determine which blood samples will be extracted
for genetic testing), participants are considered rando-
mized whether or not they attend the counseling appoint-
ment and will be analyzed in an intent-to-treat manner.
Genetic testing
To date, single nucleotide polymorphisms (SNPs) that
have been associated with DM are weakly associated,
typically yielding odds ratios (OR) <2.0, although combi-
nations of multiple SNPs have resulted in larger ORs
[10]. We are examining how genetic informationMethod
Electronic data pull
Electronic data pull (≥ 26 kg/m2 to allow for
error), screening telephone call, and confirmed
at baseline visit
Electronic data pull, confirmed in telephone call
occasion Electronic data pull
Electronic data pull
Electronic data pull, confirmed in telephone call
onths Screening telephone call
lifestyle changes Screening telephone call
questions unassisted Screening telephone call
e Screening telephone call
ve impairment [7] Screening telephone call
Baseline visit
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markers with small ORs may affect health behaviors. We
selected 3 DM-related genes (TCF7L2, PPARg, and
KCNJ11) in which to test SNPs because, when we
designed this study, they were among the most studied
SNPs, even in populations of varying ethnicities [10].
The Duke Clinical Molecular Diagnostics Laboratory
is performing the genetic testing. The regions of the
KCNJ11, PPARG, and TCF7L2 genes, which encompass
the desired single nucleotide polymorphisms of interest
[Rs5219T >C, Rs1801282C>G, Rs7903146C>T, re-
spectively], are amplified using three primer pairs. Puri-
fied genomic DNA is used for polymerase chain reaction
(PCR). The primers used in the PCR reactions contain
M13 universal primer “tails” at their 5′ ends and have 3′
ends that are homologous to their genomic target se-
quence. The resulting PCR products are treated with an
exonuclease/ phosphatase mixture (ExoSAP-IT: USB
Corporation) to remove excess PCR primers and nucleo-
tides. These purified DNA amplicons are then sequenced
using universal M13 forward and reverse primers [M13
Forward (17 bp) and M13 Reverse (17 bp)] and the Big
Dye Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems). These products are then purified with the Big
Dye XTerminator Purification Kit (Applied Biosystems)
and resolved using the ABI 3130xl Genetic Analyzer.
Data are analyzed using the ABI Data Collection software
v3.0, Sequencing Analysis software v5.2 and SeqScape
software v2.5. Sequences are compared to the reference
DNA sequence (GenBank accession: K:NT_009237.18,
P:NT_022517.18, T:NT_030059.12).
Risk stratification
We provide patients with risk estimates for up to four dif-
ferent DM risk factors (lifetime risk based on age, sex, race,
and BMI; risk based on family history; risk based on FPG
level; and, for those randomized to the CR+G group, risk
based on genetic testing for 3 DM-related genes) rather
than one global DM risk value because there is no well-
validated algorithm that incorporates various DM riskTable 2 Low, moderate, and high-risk values for each risk cat
Risk category Low risk Moderate risk
population-based risk <20% 20-40%
Family history Only (1) one second-degree
relative with DM from one or
both sides of family; or no
family history of DM
Only (1) one first- a
relative with DM fro
first-degree relative
father with DM; or
relatives from same
Fasting plasma
glucose (FPG)
<100 mg/dl 100-109 mg/dl
Copies of high-risk
alleles from TCF7L2,
PPARg, KNCJ11
(possible range 0–6)
0-2 3
* Participants with FPG >125 mg/dl are excluded.factors into a single prediction score similar to the Fra-
mingham risk score for cardiovascular disease risk. We
categorize participants’ risk into three levels based on vali-
dated algorithms (low, moderate, or high; Table 2) to pro-
vide patients with a means of “fairly” comparing their risk
across the different measures given the fact that the refer-
ence groups for the numerical risk categories often differ
(e.g., lifetime DM risk based on BMI, race, sex, and age
being presented as a percentage versus DM risk based on
FPG being presented as an odds of developing DM in the
next 5 years). Furthermore, numerical risk information
tends to be poorly understood by patients [11], particularly
when information is unfamiliar and presented in isolation
[12,13]. Rather, people tend to focus more on the gist of
risk information [14].
Population-based risk estimates are taken from lifetime
risk tables based on age, sex, race, and BMI [15]. We clas-
sified <20% lifetime risk as low, 21-40% as moderate, and
>40% as high. Family history of DM is based on first- and
second-degree relatives, and classification into risk levels
is based on a published algorithm [16]. Although the
American Diabetes Association guidelines consider pre-
diabetes present when FPG >100-125 mg/dl, analyses indi-
cate a high false-positive rate for values between 100 and
109 mg/dl [17]. Therefore, participants are classified
according to whether their FPG is <100 mg/dl (low), 100–
109 mg/dl (moderate), or 110–125 mg/dl (high). Partici-
pants with baseline FPG >125 mg/dl become ineligible
and are encouraged to follow-up with their primary care
provider. Based on the distribution of the possible combi-
nations of the high-risk alleles that we are testing in a pre-
vious study [10], we designated 0–2 high-risk alleles as
low risk, 3 as moderate, and 4–6 as high risk.
Development of risk counseling protocol
Conventional risk counseling (both arms)
All counseling in both arms is delivered by the same
genetic counselor to avoid the possibility that differ-
ences between arms could be attributed to theegory
High risk
>40%
nd one second-degree
m same lineage; (2) one
with DM; (3) mother and
(4) two second-degree
lineage with DM
At least (1) two first-degree relatives with DM
from same lineage; (2) one first- and two
second-degree relatives with DM from same
lineage; or (3) three second-degree relatives
with DM from same lineage
110-125 mg/dl*
4-6
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risk counseling in the CR+E arm. One genetic
counselor (AS) performed the counseling for the first
342 randomized participants, and a second genetic
counselor is performing the genetic counseling for the
remaining randomized participants. Analyses will ex-
plore effects by counselor.
The counseling protocol comprises a flipbook with
written and graphical information accompanied by an
oral presentation. The session begins with a definition of
DM and its prevalence, possible negative outcomes, and
risk factors. The counselor briefly mentions that genes
are involved in the development of DM and emphasizes
that, although family history incorporates genetic infor-
mation, family history also reflects shared lifestyle and
environment. Next, the counselor provides participants
with personalized risk estimates for lifetime risk, family
history, and FPG.
To evaluate different ways of presenting personalized
risk information, we pilot tested the counseling protocol
in 25 patients meeting eligibility criteria. In a previous
study, a vertical bar graph and a thermometer, accom-
panied by color, were preferred methods of conveying
cardiovascular risk level by providers and patients [18].
Therefore, in our pilot study, we presented risk levels in
a vertical thermometer format with low risk level col-
ored green, moderate colored yellow, and high colored
red. A colored arrowhead denotes the risk level posi-
tioned on the thermometer graph at the value of the risk
factor (Figure 2).
At the end of the counseling session, CIV conducted
qualitative interviews to examine participants’ inter-
pretation of the information, solicit feedback on the
counseling protocol, and evaluate different pictorial
presentations of personalized risk information. Specific-
ally, participants viewed a pie graph, a vertical bar
graph, a horizontal bar graph, and a speedometer, all
in black and white and in color versions (low risk = green,
moderate risk = yellow, high risk = red). Participants were
asked to compare the graphs, indicate which best con-
veyed risk level, and for their interpretation of the
descriptors and colors. Participants preferred the vertical
thermometer, indicated that the colors aided in interpret-
ation of the risk level, and indicated that the colors
matched the descriptors.
Genetic risk (CR +G)
The genetic counselor provides a brief review of genetics
and indicates that studies have linked several genes to
the development of DM. The genetic counselor further
indicates that genetic testing for DM does not yield de-
finitive risk estimates, but rather that it supplements the
risk information already considered with the other three
risk categories. Next, the genetic counselor providesparticipants with their personal genetic testing results in
a manner similar to the other risk estimates using a ver-
tical thermometer bar graph (last graph in Figure 2).
The genetic counselor emphasizes that we tested only
three of several genes that are associated with increased
DM risk and that lifestyle modification can prevent or
delay the onset of DM even if genetic results indicate an
increased risk.
Control counseling (CR + E)
To ensure that the control arm (CR+E) receives equal
duration of genetic counselor contact, information is
reviewed for age-related macular degeneration, cataracts,
and glaucoma. We chose this control topic because the
lifestyle modifications recommended to prevent these
eye diseases overlap little with those recommended to
prevent DM. Additionally, although DM is a risk factor
for eye disease, we chose eye disease topics that would
not emphasize this risk so that the information pre-
sented would be unlikely to add to control participants’
motivation to prevent DM. Participants receive informa-
tion about risk factors, screening, and behaviors to re-
duce their risk for the three eye diseases, although no
individualized risk information is presented. Ten pilot
participants completed a risk counseling session with
eye counseling instead of genetic counseling to ensure
that participants understood the information and to
match the duration of the eye disease counseling to the
duration of the genetic counseling (approximately 10
min). Thus, any difference between arms could not be
attributed to the increased amount of time spent with
participants in the CR+G arm, but rather the content of
the genetic counseling.
Lifestyle counseling (both arms)
Following genetic or eye disease counseling, the genetic
counselor engages participants in brief lifestyle counsel-
ing. The counselor informs participants that lifestyle
changes can help ameliorate risk, even in the presence
of family history or genetic abnormalities. Using a
semi-structured script that operationalizes some basic
principles of motivational interviewing, the genetic
counselor encourages participants to set physical activ-
ity and/or dietary intake goals, with an emphasis on
simple, short-term, and measurable goals [6]. Goals are
recorded on a sheet to take home, and participants are
encouraged to review their progress monthly and adjust
goals accordingly. Participants are provided with a sum-
mary statement containing their risk information, in-
cluding genetic testing results if in the CR+G arm; the
National Institutes of Health Game Plan resources,
which are based on the Diabetes Prevention Program
and provide comprehensive information about DM
and tools for adopting prevention behaviors; an
Figure 2 Sample graphs for lifetime risk, family history, fasting plasma glucose, and genetic testing.
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list of resources available at VA, including website
addresses. Participants in the CR+G arm also receive
the NHGRI publication A Guide to Your Genome to aid
in genome science education and comprehension of
genetic information. Participants receive $25 for this
visit, which can take up to 1.5 h.
Measures
Demographics are assessed at baseline by an RA.
Psychological outcomes are assessed by the genetic
counselor immediately following the risk counseling.The remaining outcomes are assessed by a blinded RA
at 3 and 6 months, with 3 months as the primary end-
point. Participants receive $25 for the 3- and 6-month
outcome visits.
Primary outcome
The primary outcome is weight because it is sensitive to
lifestyle modifications [19] and is highly correlated
within an individual over time, even in studies of inten-
sive weight loss interventions [20]. Weight change was
more influential than physical activity level or dietary fat
intake for the prevention of DM in the Diabetes
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standardized digital scale, with participants wearing light
clothing and with accessories and shoes removed.
Psychological outcomes
Likelihood is assessed with the item, “What are your
chances of getting type 2 diabetes in your lifetime?”
(1 = definitely will not get diabetes to 7 = definitely will
get diabetes). The Brief Illness Perception Questionnaire
measures dimensions of illness captured by the Com-
mon Sense Model, including consequences, timeline,
personal control, treatment control, identity, concern,
understanding, emotional response, and causal attribu-
tions [22]; items are modified to focus on developing
DM in the future as opposed to now. Readiness to
change diet and increase physical activity is assessed
with single items [23]. Self-efficacy to follow a diet is
assessed with the revised Eating Self-Efficacy Scale [24].
Self-efficacy to engage in physical activity is assessed
with the Self-Efficacy for Exercise scale [25]. Intentions
to modify dietary intake and increase physical activity
are assessed with seven semantic differential items.
Reactions to genetic testing
The Multidimensional Impact of Cancer Risk Assess-
ment Questionnaire is administered in the CR+G arm
only at 3 and 6 months to assess the psychosocial impact
of receiving a genetic test result and was adapted for
DM [26].
FPG, fasting insulin, and homeostasis model assessment of
insulin resistance (HOMA-IR)
Improvements in insulin action are assessed by measure-
ment of FPG and insulin levels, with subsequent calcula-
tion of HOMA-IR. Hemoglobin A1c was not measured
because it was not recommended for diagnosis of DM
when the study began.
Dietary intake
Dietary intake is assessed with the Block Brief 2000 Food
Frequency Questionnaire, which includes color photos
representing portion sizes to aid participants in estimat-
ing typical portion size, and instructions ask participants
to check off foods they have eaten during the past 3
months, indicating portion size and how often they eat
each item.
Physical activity
Daily physical activity is assessed by the long version of
the International Physical Activity Questionnaire (IPAQ)
[27], which assesses activity over the past 7 days in the
domains of occupation, transportation, yard/garden,
household, leisure, and sitting. The IPAQ provides esti-
mates of metabolic equivalent tasks energy expenditure,which can be reported for each activity or as a total
score.
Utilization of weight loss resources
Participants rate how frequently they have used the fol-
lowing resources since their risk counseling session
(never, rarely, sometimes, and often): written materials
provided during the counseling session; MyHealtheVet, a
website for veterans that offers health resources; other
websites; home exercise equipment; books related to life-
style changes; medication to prevent DM; weight loss
medication; weight loss surgery; the VA’s MOVE! weight
loss program; a personal trainer; a nutritionist; a weight
loss program; recreation center or fitness facility; park or
greenway; and physician-recommended regimen.
Primary analysis
Primary analyses will be conducted on an intent-to-treat
basis; participants will be analyzed in the group to which
they were assigned, regardless of whether they attend
the counseling session, using all available data [28]. Stat-
istical analyses will be performed using SAS for Win-
dows (Version 9.2: SAS Institute, Cary, NC) and R
(http://www.R-project.org).
Our primary hypothesis is that mean weight loss in
the CR+G group will be at least 6 lbs greater than in
the CR+E group after 3 months. Weight is a continuous
variable, and we will fit longitudinal models examining
the short-term effects of the intervention using linear
mixed models [29], where the baseline and 3-month
weight measurements will be part of the outcome vector.
This method handles dropouts in a principled manner.
Depending on the type and scope of missing data, we
will also explore multiple imputation as a strategy to use
in conjunction with our primary analytic tools [30].
Secondary analyses
The secondary hypotheses of this study are that mean
perceived risk in the CR+G group will be greater than
in the CR+E group immediately following counseling;
that mean improvements in physical activity, caloric in-
take, and insulin resistance in the CR+G group will be
greater than in the CR+E group after 3 months; and
that mean improvements in weight loss, physical activity,
caloric intake, and insulin resistance in the CR+G group
will be greater than in the CR+E group after 6 months.
Because all secondary outcomes are continuous, we will
use the same analysis plan as for the primary outcome
analysis. Hypotheses concerning perceived risk and the
3-month outcomes will be tested by the coefficient for
the treatment × time interaction. For the hypothesis con-
cerning 6-month outcomes, the models will include an
additional time point. We will examine the treatment ×
time interaction, and, using contrasts among the model
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ences after 3 and 6 months of follow-up. We expect the
effect of the genetic testing to be largest at the 3-month
time point because it is in closer proximity to the coun-
seling session. A 6-month between-group difference that
remains significant and is of similar magnitude to the
3-month difference would imply that the intervention
effect was sustained.
Power and sample size considerations
We plan to enroll 300 participants in each arm of the
study (total n = 600). Our power calculation is based on
our primary outcome of weight, under the null hypoth-
esis that there will be no between-group difference in
weight at the 3-month time point. The sample size is
based on methods appropriate for analysis of covariance
analyses in randomized trials [31], where we applied a
two-sample t-test sample size calculation for the
between-group difference at the 3-month time point
multiplied by a factor 1-(rho)2, where rho represents the
Pearson correlation between baseline and 3-month time
point outcome measures.
Based on our prior work [32], we estimated a standard
deviation of approximately 55 lbs at the 3-month time
point and a correlation of 0.90 between baseline and 3-
month weights. Using these variability and correlation
estimates, and assuming an attrition rate of 10% at 3
months with an α= 0.05 (two-sided) and sample size of
300 per group, we will have approximately 80% power to
detect a 6-lb difference in weight between the CR+G
and CR+E groups. A 6-lb difference is considered clin-
ically meaningful [33] based on evidence from the
Finnish Diabetes Prevention Study, in which a net
weight loss of 7.5 lbs at 1 year reduced risk for DM by
58%.
Cost-effectiveness analysis
To assess the cost-effectiveness of the intervention, we
will examine variation in health-care and intervention
costs between CR+G and CR+E arms, and variation in
effectiveness between arms, to calculate an incremental
cost-effectiveness ratio that summarizes the relative
costs and benefits of the genetic counselor-led inter-
vention. The effectiveness measure will be weight (in
pounds). To conduct the cost-effectiveness analysis from
a “limited” social perspective [34], several additional
costs will be collected beyond health-care costs, includ-
ing intervention costs incurred by study staff and
patients, patient out-of-pocket and travel costs, and in-
direct costs incurred by patients because of loss of
productivity.
To capture the amount of time the genetic counselor
spends with each patient and the total amount of time
spent documenting interactions with the patients, and todifferentiate these intervention activities from research
activities, the genetic counselor logs these time commit-
ments by patient and date. Intervention costs attribut-
able to the RA, project coordinator, study investigators,
and genetic counselor will be based on the specific
personnel’s annual salary plus benefits. Costs for inter-
vention supplies (computers, office furniture, and tele-
phones) will be based on their acquisition price from
the manufacturer, and office space will be calculated
based on standard VA rates and will be allocated over
their expected lifetime of use. Patient time costs will be
based on hourly wages calculated from Bureau of Labor
Statistics data and on the average amount of time spent
in the intervention, not counting outcome assessments.
Discussion
Incorporating genetic testing for common, complex
chronic diseases such as DM requires resources not
commonly found in primary care settings, including gen-
etic testing capabilities and genetic counselors. We
developed a risk counseling protocol for conventional
DM risk factors and the addition of genetic testing
results, which is being evaluated in a randomized trial of
600 participants. The results of the trial will contribute
to the evidence base of the clinical utility of genetic in-
formation for motivating patient behavior change.
Limitations
One possible limitation of this study is that, despite
many patients’ enthusiasm for genetic testing, as docu-
mented in the existing literature and in our pilot study
of veterans, some patients may be reticent to undergo
genetic testing. Therefore, our recruitment rate may be
lower than for studies not using genetic testing. Yet,
given the large number of patients (>5,700) at the Dur-
ham VAMC who are aged 21–65, BMI ≥ 27 kg/m2, with
no prior diagnosis of DM, we should have more than ad-
equate numbers from which to recruit.
Another limitation is the relatively low intensity of the
genetic counseling. Sensitive to the fact that we are not
testing a lifestyle change intervention per se, but the ef-
fect of additional, specific knowledge of genetic risk fac-
tors, we purposefully refrained from using an intensive
patient intervention, relying instead upon the measure-
ment of behaviors and sensitive clinical outcomes
(weight, FPG, insulin) and a large sample size to com-
pensate for the possibility that observed effect sizes will
be small. If the genetic counseling shows promise for
motivating lifestyle behavior change, then pairing it with
a counseling program may ultimately enhance its
effectiveness.
Additionally, we are using only three of several genes
that have been associated with DM for the genetic com-
ponent of the risk counseling. We chose these three
Voils et al. Trials 2012, 13:121 Page 9 of 10
http://www.trialsjournal.com/content/13/1/121genes based on their strength and consistency of associ-
ation among numerous studies and populations, recog-
nizing that including additional genes might improve the
accuracy of the risk information marginally. The number
of genes associated with DM increases over time so that
additional associations will be found as this study is con-
ducted. The purpose of this study is to evaluate the be-
havioral impact of genetic risk information rather than
to optimize the accuracy of the information.
Finally, due to the relatively short duration of the
study, weight is used as a surrogate for the incidence of
DM. Future studies may examine whether genetic test-
ing prevents or delays the onset of DM.
Strengths
The current study will address limitations of previous
studies and advance our knowledge about the role of
genetic testing for a chronic disease in the following
ways. First, the proposed study will be among the first to
determine whether genetic risk counseling for DM
results in significant changes in health behaviors and
clinical outcomes.
Another strength is that the RCT design will allow us
to assess whether any changes in health protective beha-
viors occur because of the addition of genetic counseling
to conventional risk counseling. Most studies of the ef-
fect of genetic counseling have been observational, limit-
ing the conclusions that can be drawn [35].
Finally, a genetic counselor delivers the genetic results,
representing the best-case scenario to determine the effi-
cacy of genetic risk counseling. If this study proves posi-
tive, then we will have developed a model that could
perhaps be expanded using other types of providers,
who would be more likely to use genetic testing in pri-
mary care (e.g., internists, nurse practitioners, physician
assistants).
Conclusion
A standardized protocol for delivering risk reduction
counseling to patients at risk for developing DM has
been developed and could be incorporated into primary
care. Results of the trial will inform policy about whether
this counseling should additionally include genetic test-
ing results. Genetic testing is becoming more wide-
spread, appearing more in clinical settings and now
offered as a direct-to-consumer service that can be pur-
chased from a website and performed simply by mailing
in a saliva sample [1,36]. Novel diagnostic tests are
sometimes integrated into practice before understanding
their full impact on diagnostic and treatment decisions,
or carefully weighing their physical, mental, and financial
costs. Like diagnostic tests that predict the presence of
disease, genetic risk information should be evaluated not
only for accuracy, but also for integration into clinicalcare and the ability to affect treatment decisions and
behaviors. Results from this trial will contribute to the
evidence base to inform the future consumption of gen-
etic testing for complex chronic diseases.
Trial status
Enrollment for the RCT phase of this project began
in January 2011 and will be completed in August of
2012.
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